Latest Basal cell carcinoma Stories
$1.5 million in proceeds to fund 2014 commencement of HPPI's clinical development program for repurposing the approved anti-fungal drug itraconazole for the treatment of cancer, initially for the treatment
The study met the primary endpoint with objective response rates of 41.8% and 32.5% respectively in the 200 mg and 800 mg treatment arms(1,2) EAST HANOVER, N.J., June 1, 2014 /PRNewswire/
Zoll, Kranz & Borgess, LLC, (ZKB) a pharmaceutical and medical device litigation firm, is currently investigating claims of men who developed melanoma after taking the pharmaceutical drug,
ORPINGTON, England, March 27, 2014 /PRNewswire/ -- Michelson Diagnostics, the UK based medical device company focused on multi-beam Optical Coherence
LOS ANGELES, March 11, 2014 /PRNewswire/ -- - Los Angeles dermatologist, Dr.
The Sensus Healthcare SRT-100™ is a non-invasive skin cancer treatment system.
LOS ANGELES, Feb. 26, 2014 /PRNewswire/ -- Los Angeles dermatologist, Dr.
Primary Care Physicians will soon be able to test for basal cell carcinoma, the most common cancer in the US GARDEN CITY, N.Y., Feb.
- A trick or prank.